Quantcast

Latest Retinopathy Stories

2014-10-18 12:21:24

Study shows iPhone ophthalmoscope could be an effective, lower-cost solution for monitoring diabetic retinopathy in remote populations CHICAGO, Oct. 18, 2014 /PRNewswire/ -- A smartphone-based tool may be an effective alternative to traditional ophthalmic imaging equipment in evaluating and grading severity of a diabetic eye disease, according to a study released today at AAO 2014, the American Academy of Ophthalmology's 118(th) annual meeting. The results of the research indicate...

2014-09-16 08:29:26

Regeneron plans to submit sBLA for this indication by year end TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA(®) (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two Phase 3 trials (VIVID-DME and VISTA-DME), in which...

2014-09-03 20:23:43

MarketOptimizer.org adds new report "Epicast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023" to its store. DALLAS, Sept. 3, 2014 /PRNewswire-iReach/ -- Macular edema (ME) occurs due to the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. In ME, fluid and protein deposits collect on or under the macula of the eye, due to a breakdown in the blood-retinal barrier. The occurrence of ME is highly frequent in...

2014-08-26 16:28:14

LONDON, Aug. 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Diabetic Retinopathy Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/diabetic_retinopathy_global_clinical_trials_review.htmlDiabetic Retinopathy Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Diabetic Retinopathy Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Retinopathy...

2014-08-07 23:04:10

Global Retinal Vein Occlusion Market 2014-2018 analyzes key players like Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc., Alimera Sciences, Bristol-Myers Squibb, NicOx, Santen Pharmaceutical and Valeant Pharmaceuticals. Dallas, Texas (PRWEB) August 07, 2014 One of the growth-pertaining trends in the market is the introduction of biologics as a treatment option for retinal vein occlusion. Drugs such as Avastin (bevacizumab) and Lucentis (ranibizumab),...

2014-08-05 12:25:50

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:U.S. Market and Survey for Retinopathy Screening Deviceshttp://www.reportbuyer.com/pharma_healthcare/diseases/u_s_market_survey_retinopathy_screening_devices.htmlAbstract:The market for diabetic retinopathy screening devices is in its infancy. Growth is expected under all forecast scenarios; however, the rate of growth will be determined by pricing and reimbursement. Several different...

2014-07-30 08:33:22

DUBLIN, July 30, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a...

2014-07-14 23:03:57

The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for diabetic macular edema (DME) patients. Hicksville and Hauppauge, NY (PRWEB) July 14, 2014 The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for...

2014-05-28 12:30:11

MORGANTOWN, W.Va., May 28, 2014 /PRNewswire/ -- The Eye Foundation of America announced today that it is working with the Gourami Eye Institute, a fully-equipped eye hospital in Rajahmundry, India (300 miles east of Hyderabad) to provide international learning opportunities for ophthalmology students who have an interest in diabetic retinopathy. The program will provide students hands-on experience performing in-the-field diabetic retinopathy preventative screenings as well as...

2014-05-12 11:53:53

Lunenfeld-Tanenbaum Research Institute Bioengineering a safe treatment for retinopathy, the leading cause of vision loss in Canada A new drug approach has been developed for safer clean-up of deformed blood vessels in the eye by a research team at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital in Toronto. The growth of malformed blood vessels that can burst is a leading cause of vision loss in North America. Retinopathy and retina degeneration are associated with...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related